Chemotherapy News and Research

Latest Chemotherapy News and Research

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

Researchers at the University of Michigan Comprehensive Cancer Center have applied advanced radiation techniques for head and neck cancer to avoid treating critical structures that affect swallowing and eating.

11 May 2010

New law could help hospice patients continue aggressive medical treatments

Kaiser Health News staff writer Jordan Rau, in collaboration with The Philadelphia Inquirer, reports: "After an excruciating bout of chemotherapy, Linda Meisenhelder gave up fighting colon cancer and last fall entered end-of-life hospice care.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough could lead to potential non-toxic therapies for cancer patients. The Foundation-funded investigators include Ari Melnick, M.D., of Weill Cornell Medical College, Alexander MacKerell, Ph.D., of the University of Maryland and Gilbert Priv-, Ph.D., of the University of Toronto.

11 May 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

First Edition: May 10, 2010

Today's health policy headlines include the feature coverage of aspects of health reform implementation, including how "gradfathering" will be defined in regulations and the latest details on the early retiree reinsurance program.

10 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

Novel imaging techniques improve post heart attack survival rates in mouse model

Human adult stem cells injected around the damage caused by a heart attack survived in the heart and improved its pumping efficiency for a year in a mouse model, researchers at The University of Texas MD Anderson Cancer Center report online ahead of publication in Circulation Research.

10 May 2010

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Gliomas arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). These tumors are graded from the lowest grade 1 to highest grade 4, with glioblastoma multiforme being the highest grade and deadliest type of glioma.

7 May 2010

Minimally invasive scopes to detect cancer

Just as cameras and televisions have been reinvented in the last decade with improved optics, sharpness and brightness, so have the tiny imaging scopes that physicians use to peer into the body's nooks and crannies -- its organs and digestive system.

7 May 2010

Kaposi's Sarcoma-associated herpesvirus replicates, spreads by hijacking PYM cellular protein

Research from the University of Leeds has identified how the virus which causes Kaposi's Sarcoma replicates and spreads - opening a door to a possible new treatment for the disease.

7 May 2010

Telik first-quarter net loss decreases to $5.3 million

Telik, Inc. today reported financial results for the first quarter ended March 31, 2010. The net loss for the quarter ended March 31, 2010 was $5.3 million, or $0.10 per share, compared with a net loss of $7.7 million, or $0.14 per share, for the same period in 2009.

7 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

SCOLR Pharma, Inc. today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation, (RedHill), granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's proprietary extended delivery technology (CDT). Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and radiation related nausea and vomiting.

6 May 2010

Researchers demonstrate how Plasmodium falciparum can able to circumvent action of artemisinin

Researchers from CNRS, INSERM and Toulouse University Hospital have demonstrated how the parasite Plasmodium falciparum, which causes severe forms of malaria, is able to circumvent the action of artemisinin and its derivatives, which are today the first-line drugs used to treat this disease. This study supplies some important findings that will enable a clearer understanding of the mechanisms of resistance to antimalarial drugs and the testing of novel therapeutic strategies in a context where the drug resistance of parasites is of increasing concern.

6 May 2010

Swedish Cancer Institute, Elekta renew partnership to continue flow of technology, services to cancer patients

Swedish Cancer Institute and Elekta launch renewed partnership agreement to continue the flow of world-class technology, services to cancer patients in the Pacific Northwest and beyond.

From Elekta 6 May 2010

Round-up: Minnesota budget news; Coverage expansions in S.D. and Oregon; and states' opposition to federal health reform

The Minnesota House passed a bill on health care Tuesday that readies the state for implementing the federal health care overhaul and makes $170 million in cuts to mental health and other social programs, The (St. Paul, Minn.) Pioneer Press reports. Gov. Tim Pawlenty has promised to veto the bill over what he sees as a tax increase.

6 May 2010

New blood test could increase success of lung cancer drug erlotinib: Study

A new blood test could increase the success of a popular lung cancer drug called erlotinib by allowing doctors select which patients will react positively to the drug.

6 May 2010

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2010, and provided an update with respect to the Company's key business initiatives.

6 May 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

New law could help hospice patients continue aggressive medical treatments

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Immunomedics third-quarter revenues increase to $10.7 million

First Edition: May 10, 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Novel imaging techniques improve post heart attack survival rates in mouse model

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Minimally invasive scopes to detect cancer

Kaposi's Sarcoma-associated herpesvirus replicates, spreads by hijacking PYM cellular protein

Telik first-quarter net loss decreases to $5.3 million

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

Researchers demonstrate how Plasmodium falciparum can able to circumvent action of artemisinin

Swedish Cancer Institute, Elekta renew partnership to continue flow of technology, services to cancer patients

Round-up: Minnesota budget news; Coverage expansions in S.D. and Oregon; and states' opposition to federal health reform

New blood test could increase success of lung cancer drug erlotinib: Study

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in